The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Validity and Clinical Utility of the Aspartate Aminotransferase–Alanine Aminotransferase Ratio in Assessing Disease Severity and Prognosis in Patients With Hepatitis C Virus–Related Chronic Liver Disease
Abstract
BACKGROUND: The aspartate aminotransferase-alanine aminotransferase ratio (AST/ALT ratio) has been used to noninvasively assess the severity of disease in patients with chronic liver disease (CLD). We previously demonstrated that progressive liver functional impairment is associated with an increase in the AST/ALT ratio. OBJECTIVES: To evaluate the reproducibility and transportability of the AST/ALT ratio in a large cohort of patients with different degrees of hepatitis C virus (HCV)-related CLD, to confirm the correlation between progressive impairment of liver function and increase in the AST/ALT ratio, to evaluate whether diagnostic accuracy of the ALT/AST ratio can be improved by using it with other biochemical variables, and to assess the 1-year prognostic capability of the AST/ALT ratio in patients with liver cirrhosis. PATIENTS AND METHODS: We retrospectively evaluated 252 patients with HCV-related CLD. The AST/ALT ratio was correlated with the degree of liver fibrosis in patients with chronic hepatitis and with the Child-Pugh score in patients with cirrhosis. All patients had undergone monoethylglycinexylidide (MEGX) testing to evaluate liver function. We assessed the prognostic ability of the AST/ALT ratio in a subset of 63 cirrhotic patients who were followed up for at least 1 year. RESULTS: The AST/ALT ratio was more frequently 1 or higher in cirrhotic patients (P<.001). There was a significant correlation between MEGX values and the AST/ALT ratio (r(s) = -0.621, P<.001). Multivariate stepwise logistic analysis showed that AST/ALT ratio, platelet count (PLT), MEGX values, and prothrombin activity were independently associated with the presence of cirrhosis. Combined assessment of the AST/ALT ratio and/or PLT obtained 97.0% positive predictive value and 97.9% negative predictive value for the diagnosis of cirrhosis. The AST/ALT ratio had 81.3% sensitivity and 55.3% specificity in identifying cirrhotic patients who died within 1-year of follow-up. CONCLUSIONS: The AST/ALT ratio is both reproducible and transportable in patients with HCV-related CLD. The AST/ALT ratio is correlated with both histologic stage and clinical evaluation. Progressive liver functional impairment is reflected by an increase in the AST/ALT ratio. Noninvasive evaluation by means of the combined AST/ALT ratio and PLT assessment misclassifies only a few cirrhotic patients. In cirrhotic patients, the AST/ALT ratio provides medium-term prognostic information that is no different from that provided by established prognostic scores.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941 · cited 1×
“Clinical severity of liver disease in cirrhotic patients was evaluated by means of the Child-Pugh score, calculated on the day of biochemical and functional evaluation.(21) All patients had undergone monoethylglycinexylidide (MEGX) testing at the time of liver biopsy (chronic hepatitis) or clinical evaluation (cirrhos…”
MethodA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610
Classification of chronic viral hepatitis: a need for reassessment
Scheuer, P. J. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90084-o · Cited by 1,576
AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection
Sheth, S. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(97)00009-9 · Cited by 583
Estimating future hepatitis C morbidity, mortality, and costs in the United States
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.10.1562 · Cited by 567
Variability of hepatitis C virus
Simmonds, P. (1995) · Hepatology · doi:10.1002/hep.1840210243 · Cited by 567
Ratio of Serum Aspartate to Alanine Aminotransferase in Chronic Hepatitis Relationship to Cirrhosis
Williams, A. L. B., & Hoofnagle, J. H. (1988) · Gastroenterology · doi:10.1016/s0016-5085(88)80022-2 · Cited by 513
Sorbi, D. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00061-1 · Cited by 466
The SGOT/SGPT ratio?An indicator of alcoholic liver disease
Cohen, J. A., & Kaplan, M. M. (1979) · Digestive Diseases and Sciences · doi:10.1007/bf01324898 · Cited by 450
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Liver enzyme alteration: a guide for clinicians
Giannini, E. G. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040752 · Cited by 2,016
Self-citationDiagnosis of cirrhosis by transient elastography (FibroScan): a prospective study
Foucher, J. (2006) · Gut · doi:10.1136/gut.2005.069153 · Cited by 1,284
Evaluation of Liver Fibrosis: A Concise Review
Afdhal, N. H., & Nunes, D. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30110.x · Cited by 622
Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection
Adams, L. A., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G. W., & Jeffrey, G. P. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.048389 · Cited by 539
Ganne-Carrié, N., Ziol, M., de Ledinghen, V., Douvin, C., Marcellin, P., Castera, L., Dhumeaux, D., Trinchet, J.-C., & Beaugrand, M. (2006) · Hepatology · doi:10.1002/hep.21420 · Cited by 508
HIGH AST/ALT RATIO MAY INDICATE ADVANCED ALCOHOLIC LIVER DISEASE RATHER THAN HEAVY DRINKING
NYBLOM, H. (2004) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh074 · Cited by 474
Chou, R., & Wasson, N. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00005 · Cited by 370
Noninvasive Measures of Liver Fibrosis
Rockey, D. C., & Bissell, M. D. (2006) · Hepatology · doi:10.1002/hep.21046 · Cited by 349
Lackner, C., Struber, G., Liegl, B., Leibl, S., Ofner, P., Bankuti, C., Bauer, B., & Stauber, R. E. (2005) · Hepatology · doi:10.1002/hep.20717 · Cited by 340
Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?
Huitzil-Melendez, F.-D., Capanu, M., O'Reilly, E. M., Duffy, A., Gansukh, B., Saltz, L. L., & Abou-Alfa, G. K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9895 · Cited by 335
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy
Sebastiani, G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i23.3682 · Cited by 266
A Systematic Review of the Quality of Liver Biopsy Specimens
Cholongitas, E., Senzolo, M., Standish, R., Marelli, L., Quaglia, A., Patch, D., Dhillon, A. P., & Burroughs, A. K. (2006) · American Journal of Clinical Pathology · doi:10.1309/w3xc-nt4h-kfbn-2g0b · Cited by 264
Metadata
- Authors
- Giannini, E., Risso, D., Botta, F., Chiarbonello, B., Fasoli, A., Malfatti, F., Romagnoli, P., Testa, E., Ceppa, P., & Testa, R.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2003-01-27
- Volume
- 163
- Issue
- 2
- Pages
- 218
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2116874804
- Cited by
- 377
- References
- 33
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.